Schizophrenia Clinical Trials

Effectiveness of switching from injectable conventional antipsychotic medications to injectable risperidone (PI: H. Nasrallah)

Eligibility
• Adults (at least 18 years old) with a diagnosis of schizophrenia or schizoaffective disorder who are currently receiving a first generation depot antipsychotic and have residual symptoms or side effects from this medication
• Outpatient

Patient Benefits
• Eligible participants may receive study medication and study-related procedures/visits at no cost, and compensation for participation, time, and travel
• Open-label to patient, prescribing physician, and study coordinator

Contact Information
Tracie Northern
(513) 558-0659
Tracie.Northern@uc.edu

Eligibility
• Adults (at least 18 years old) with a diagnosis of schizophrenia or schizoaffective disorder who are currently receiving two antipsychotic medications and have residual symptoms or side effects from these medications
• Outpatient

Patient Benefits
• Eligible participants may receive study medication and study-related procedures/visits at no cost, and compensation for time and travel
• Open-label to patient, prescribing physician, and study coordinator

Contact Information
Tracie Northern
(513) 558-0659
Tracie.Northern@uc.edu

Clinical management of metabolic problems in patients with schizophrenia: switching to aripiprazole versus continued treatment with olanzapine, quetiapine, or risperidone (PI: H. Nasrallah)

Eligibility
• Adults (at least 18 years old) with a diagnosis of schizophrenia or schizoaffective disorder who are currently receiving olanzapine, quetiapine, or risperidone and have residual symptoms or side effects from this medication
• Outpatient

Patient Benefits
• Eligible participants may receive study medication and study-related procedures/visits at no cost, and compensation for time and travel for outpatient visits only
• Open-label to patient, prescribing physician, and study coordinator

Contact Information
Tracie Northern
(513) 558-0659
Tracie.Northern@uc.edu